June 25, 2024
1 min watch
Save
VIDEO: Notal Vision celebrates FDA authorization of AI-powered Scanly Home OCT device
Issue: July 25, 2024
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Kester Nahen, PhD, CEO of Notal Vision, discusses the patient self-operated AI-powered Scanly Home OCT device.
The Scanly Home OCT, the first home imaging device in ophthalmology to receive FDA authorization, utilizes an AI algorithm to process images from OCT devices to monitor patients with neovascular age-related macular degeneration, according to Nahen.
“We are right now in communications with Medicare about coverage and payment for the billing codes that allow both the monitoring center as well as physicians to bill the services they provide,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Nahen reports being the CEO of Notal Vision.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.